Biotech Won the Tape. One Chip Giant Won the Quarter’s Dollars

The third quarter’s cleanest shift was healthcare’s move from pipeline promise to aftermarket leadership. Healthcare and biotech supplied 11 of the 32 tracked debuts, more than any other sector, and averaged a 15.2% first-day return and a 12.9% return at the September 30 mark. Technology raised nearly $29.24 billion, but that was primarily a scale event: SK hynix alone accounted for $26.51 billion, or 79.6% of all tracked proceeds.

That distinction matters. The quarter did not deliver a broad technology reopening. Excluding SK hynix, technology raised about $2.73 billion across seven names and averaged an 8.2% first-day loss and a 15.6% decline at quarter-end. The giant semiconductor cross-listing, which priced its ADSs at $149, was real demand: Reuters reported a $26.5 billion raise, and the shares finished their first session 13.1% above the offer. IPOGrid reads the sector total as one exceptional liquidity event, not evidence that investors bought technology indiscriminately.

The quarter by sector

Returns are simple averages through the September 30 measurement. Proceeds are gross base-deal amounts where available; exercised overallotments can make final closing totals higher. See the interactive sector-proceeds chart.

Biotech produced the repeatable wins

Healthcare’s advantage was breadth rather than one outlier. Braveheart Bio delivered the sector’s best first-day return at 65.6%, while Apnimed held the best current return at 55.4%. Scribe Therapeutics and Vogenx were also above 37% at the quarter-end mark. There were misses, including Standard Nuclear, Electra Therapeutics and Lyntris, but the sector median current return was still 11.4%.

The demand signal was visible in deal construction. Braveheart priced at $18, above its marketed range, and its fully exercised offering ultimately closed at $439.9 million. Apnimed priced an upsized $192 million base deal at the top of its range; the company later reported $220.8 million including the overallotment. ADARx was the sector’s largest base deal at $446.25 million, pricing 26.25 million shares at $17; AbbVie separately agreed to invest at the IPO price. Our interpretation is that investors paid for late-stage or strategically validated programs, not for a blanket biotech beta trade.

Metric leaders need context

Consumer discretionary had only two names. Jersey Mike’s was the sector’s largest deal at $1.0 billion, while Reformation posted its best first-day and current returns, 0.5% and 7.5%. The sample is too small for a sector verdict. Jersey Mike’s sold 43.48 million shares at $23, but only 13.78 million were primary shares; its final prospectus says proceeds to the company were directed in part toward debt repayment. The reviewer’s concern is that a headline-size offering does not automatically translate into an equally large balance-sheet infusion.

Financials require an even larger asterisk. Orion180 was the largest deal at $240 million, but it priced at $12, below its $15-to-$17 range, and opened at $11.50; it ended the quarter 17.5% below offer. CSB Financial had the sector’s best first day at 26.0%. Cartesian Growth Corp II showed the best current return at 220.5%, but that calculation runs from an $0.11 reference price to $0.3525. Two other acquisition-company securities also carried sub-$1 reference prices. IPOGrid reads the 36.7% financial-sector average as mathematically correct but economically unrepresentative of ordinary IPO performance.

Elsewhere, the groups were thin. Londian Wason was the industrials’ largest deal and best performer by both return measures, but only three industrial names traded and the group’s average current return was negative. Ticketplus was the sole media and communications deal and fell 8.4% by quarter-end. In technology, Bending Spoons led first-day performance at 39.7%, while ADVANTEST had the best current return at 25.7%; neither changes the sector’s negative average.

The read-through

Q3 raised $33.31 billion across the tracked set, yet $6.80 billion remained after removing SK hynix. That is the quarter in one subtraction. Capital was available in enormous size for a proven AI-memory leader and in repeatable, smaller blocks for selected drug developers. It was much less forgiving toward undifferentiated technology, and late-quarter pricing discipline was visible in Orion180’s cut below range. With Oura postponing a planned offering as the quarter closed, we would frame the market as open but selective: sector labels mattered less than maturity, sponsorship and the credibility of the use of proceeds.